» Articles » PMID: 31472149

SHCBP1 Promotes Cisplatin Induced Apoptosis Resistance, Migration and Invasion Through Activating Wnt Pathway

Overview
Journal Life Sci
Publisher Elsevier
Date 2019 Sep 1
PMID 31472149
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Lung cancer is the leading cause for cancer death due to refractory nature to current treatment strategies, understanding the regulatory mechanism of therapy resistance of lung cancer is important for lung cancer therapy. Here, we aimed to study the role of SHCBP1 in lung cancer cisplatin resistance, we found SHCBP1 was upregulated in lung cancer tissues and cells, patients with high SHCBP1 had poor prognosis. SHC binding and spindle associated 1 (SHCBP1) overexpression promoted cisplatin induced apoptosis resistance, migration and invasion determined by apoptosis assay and transwell assay with or without Matrigel, while SHCBP1 knockdown inhibited cisplatin induced apoptosis resistance, migration and invasion. Wnt pathway promoted lung cancer progression, we found SHCBP1 activated Wnt pathway, characterized by promoting β-catenin nuclear translocation. Inhibition of Wnt pathway in SHCBP1 overexpression cells reversed the effect of SHCBP1 overexpression, confirming SHCBP1 promoted lung cancer progression through activating Wnt pathway. We also found SHCBP1 expression was positively corrected with Wnt pathway activity in lung cancer samples. In summary, we found SHCBP1 promoted cisplatin induced apoptosis resistance, migration and invasion through activating Wnt pathway, providing a potential target for lung cancer therapy.

Citing Articles

Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in breast cancer.

Yang X, Yang X, Tang H, Chen X, Wang J, Zhao H Discov Oncol. 2025; 16(1):9.

PMID: 39755992 PMC: 11700959. DOI: 10.1007/s12672-025-01742-w.


Integrated machine learning to predict the prognosis of lung adenocarcinoma patients based on SARS-COV-2 and lung adenocarcinoma crosstalk genes.

Wu Y, Cui Y, Zheng X, Yao X, Sun G Cancer Sci. 2024; 116(1):95-111.

PMID: 39489517 PMC: 11711064. DOI: 10.1111/cas.16384.


SHCBP1 promotes cisplatin resistance of ovarian cancer through AKT/mTOR/Autophagy pathway.

Qi G, Ma H, Teng K, Gai P, Gong Y, Chen J Apoptosis. 2024; 30(1-2):83-98.

PMID: 39397124 DOI: 10.1007/s10495-024-02027-3.


Therapeutic potential of SHCBP1 inhibitor AZD5582 in pancreatic cancer treatment.

Ma Z, Gu Q, Dai Y, Wang Q, Shi W, Jiao Z Cancer Sci. 2023; 115(3):820-835.

PMID: 38151993 PMC: 10921007. DOI: 10.1111/cas.16059.


SHCBP1 Promotes the Proliferation of Breast Cancer Cells by Inhibiting CXCL2.

Yu X, Feng G, Nian R, Han S, Ke M, Wang L J Cancer. 2023; 14(18):3444-3456.

PMID: 38021148 PMC: 10647193. DOI: 10.7150/jca.88072.